Concepedia

Author

Ann Pope

Cancer Research UK Clinical Trials UnitORCID

Also Known As

A. Hughes, A. POPE, A. Pope, Alicia Jakeman, Ann M. Pope, Ann M. Pope, Ann Pope, Pope, Ann M., Sophia Magwaro

34

Publications

603

Citations

10

H-Index

19

Concepts

All Affiliations

Cancer Research UK Clinical Trials UnitUniversity of BirminghamUniversity Hospitals Birmingham NHS Foundation TrustBirmingham City HospitalThe Christie Hospital
AP

About

Ann Pope is an author at Cancer Research UK Clinical Trials Unit specializing in medicine, urology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

239

2

Health Sciences

2

2

90

3

Surgical Oncology

2

2

164

4

Obstetrics

1

1

12

5

Orthopaedics

1

1

27

Ann Pope

×

9

Publications

533

Citations

9

H-Index

YearCitations

Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non–muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial

Wei Shen Tan, Anesh Panchal, Laura Buckley,

European Urology

2018

137

SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease

Eleanor Barnes, Carl S. Goodyear, Michelle Willicombe,

Nature Medicine

2023

124

Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both

Nicholas D. James, Sarah Pirrie, Ann Pope,

JAMA Oncology

2016

87

Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study

Richard T. Bryan, Wenyu Liu, Sarah Pirrie,

European Urology

2021

63

TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer

Nicholas D. James, Sarah Pirrie, Ann Pope,

Health Technology Assessment

2016

54

Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).

Nicholas D. James, Sarah Pirrie, Darren Barton,

Journal of Clinical Oncology

2013

27

Cost‐effectiveness of zoledronic acid and strontium‐89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate‐refractory prostate cancer: results from the <scp>TRAPEZE</scp> trial ( <scp>ISRCTN</scp> 12808747)

Lazaros Andronis, Ilias Goranitis, Sarah Pirrie,

British Journal of Urology

2016

17

Prolapsed ureterocele: a rare vulval mass

Michael A. Miller, Andrew Cornaby, Malavika Nathan,

British Journal of Urology

1994

12

Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial

Richard T. Bryan, Wenyu Liu, Sarah Pirrie,

Journal of Clinical Oncology

2025

12

Page 1